9 Results for "

NSG

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "NSG" in MCE Product Catalog:

Cat. No.: HY-P99199
CAS No.: 946415-64-1
Synonyms: NI-0401

Target:  

CD3

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
loading...
    loading...
Cat. No.: HY-P99354
CAS No.: 2329669-78-3
Synonyms: Anti-Human CTLA4xLAG3; XmAb-22841; Pavunalimab

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-RS09593
Research Areas:  

Others

NSG1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS09594
Research Areas:  

Others

NSG2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-178775
Target:  

PI4K Parasite MAP4K PI3K

Research Areas:  

Infection

PI4K-IN-3 (Compound 27) is an orally active PI4K inhibitor with an IC50 of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and MAP4K4 kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria .
loading...
    loading...
Cat. No.: HY-148178
CAS No.: 2260904-47-8
Purity:  99.50%
Target:  

Parasite

Research Areas:  

Infection

MMV688533 is an antimalarial agent. MMV688533 interferes with intracellular trafficking, lipid utilization, and endocytosis pathways in Plasmodium falciparum. MMV688533 rapidly kills asexual blood-stage Plasmodium falciparum and Plasmodium vivax parasites in vitro and reduces parasitemia in a Plasmodium falciparum NSG mouse model. MMV688533 can be used for the research of malaria .
loading...
    loading...
Cat. No.: HY-172953
Target:  

Parasite

Research Areas:  

Infection

Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC50: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC50: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .
loading...
    loading...
Cat. No.: HY-170576
Target:  

FLT3 STAT Apoptosis

Research Areas:  

Cancer

FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC50 values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .
loading...
    loading...
Cat. No.: HY-184969
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
loading...
    loading...